- Published on
Ophthalmology – Acute Multifocal Placoid Pigment Epitheliopathy (AMPPE)
Acute multifocal placoid pigment epitheliopathy (AMPPE) is a rare, acquired inflammatory disorder affecting the retinal pigment epithelium (RPE) and choroid. It typically presents with multiple yellowish-white placoid lesions at the level of the RPE, most often involving the posterior pole and macula. The condition is frequently bilateral, and lesions are often seen in different stages of evolution, with healing characterized by areas of RPE hyperplasia. AMPPE is generally considered a self-limited condition, although it can occasionally be associated with systemic complications.
The exact incidence is unknown due to its rarity. Some genetic associations have been reported, particularly with HLA-B7 and HLA-DR2, suggesting a possible immunologic predisposition. The underlying pathophysiology is thought to involve choroidal vascular compromise, leading to secondary ischemia and inflammation of the RPE. Although the precise etiology remains unclear, approximately one-third of patients report a preceding viral-like illness, supporting the possibility of an immune-mediated or post-infectious mechanism.
Patients typically present with sudden, painless visual loss, which may affect one or both eyes. Visual symptoms can include blurred vision or scotomas. On funduscopic examination, characteristic findings include multiple, flat, yellowish-white lesions at the level of the RPE and choroid, often located in the macular region. These lesions may appear in various stages, with some resolving while others are newly forming. As lesions heal, they leave behind areas of pigmentary change due to RPE alteration.
Fluorescein angiography is helpful in confirming the diagnosis, demonstrating early hypofluorescence of the lesions due to blockage or nonperfusion, followed by late hyperfluorescence as dye leaks into the affected areas. The differential diagnosis includes other inflammatory and infectious chorioretinal diseases such as serpiginous choroiditis, ampiginous chorioretinitis, ocular toxoplasmosis, sarcoidosis, ocular lymphoma, and Vogt-Koyanagi-Harada disease.
Management is typically conservative, as most cases resolve spontaneously without treatment within several weeks. Visual recovery usually occurs over 3 to 4 weeks. In cases where the fovea is involved and vision is significantly affected, a short course of systemic corticosteroids may be considered, although evidence supporting this approach is limited. Patients should be referred to a retinal specialist for confirmation of diagnosis and monitoring.
Close follow-up is important to ensure resolution and to monitor for rare complications. Recurrence is uncommon, and repeated episodes should prompt reconsideration of the diagnosis. A critical but rare complication is cerebral vasculitis, which can be life-threatening; therefore, any associated neurological symptoms such as altered mental status require urgent neurological evaluation. The prognosis is generally favorable, with most patients regaining good visual acuity unless significant RPE damage occurs in the foveal region.
Acute multifocal placoid pigment epitheliopathy (AMPPE) is a rare, acquired inflammatory disorder affecting the retinal pigment epithelium (RPE) and choroid. It typically presents with multiple yellowish-white placoid lesions at the level of the RPE, most often involving the posterior pole and macula. The condition is frequently bilateral, and lesions are often seen in different stages of evolution, with healing characterized by areas of RPE hyperplasia. AMPPE is generally considered a self-limited condition, although it can occasionally be associated with systemic complications.
The exact incidence is unknown due to its rarity. Some genetic associations have been reported, particularly with HLA-B7 and HLA-DR2, suggesting a possible immunologic predisposition. The underlying pathophysiology is thought to involve choroidal vascular compromise, leading to secondary ischemia and inflammation of the RPE. Although the precise etiology remains unclear, approximately one-third of patients report a preceding viral-like illness, supporting the possibility of an immune-mediated or post-infectious mechanism.
Patients typically present with sudden, painless visual loss, which may affect one or both eyes. Visual symptoms can include blurred vision or scotomas. On funduscopic examination, characteristic findings include multiple, flat, yellowish-white lesions at the level of the RPE and choroid, often located in the macular region. These lesions may appear in various stages, with some resolving while others are newly forming. As lesions heal, they leave behind areas of pigmentary change due to RPE alteration.
Fluorescein angiography is helpful in confirming the diagnosis, demonstrating early hypofluorescence of the lesions due to blockage or nonperfusion, followed by late hyperfluorescence as dye leaks into the affected areas. The differential diagnosis includes other inflammatory and infectious chorioretinal diseases such as serpiginous choroiditis, ampiginous chorioretinitis, ocular toxoplasmosis, sarcoidosis, ocular lymphoma, and Vogt-Koyanagi-Harada disease.
Management is typically conservative, as most cases resolve spontaneously without treatment within several weeks. Visual recovery usually occurs over 3 to 4 weeks. In cases where the fovea is involved and vision is significantly affected, a short course of systemic corticosteroids may be considered, although evidence supporting this approach is limited. Patients should be referred to a retinal specialist for confirmation of diagnosis and monitoring.
Close follow-up is important to ensure resolution and to monitor for rare complications. Recurrence is uncommon, and repeated episodes should prompt reconsideration of the diagnosis. A critical but rare complication is cerebral vasculitis, which can be life-threatening; therefore, any associated neurological symptoms such as altered mental status require urgent neurological evaluation. The prognosis is generally favorable, with most patients regaining good visual acuity unless significant RPE damage occurs in the foveal region.
- Published on
Ophthalmology – Anisocoria in Children
Anisocoria in children refers to a difference in pupil size of 0.5 mm or more between the two eyes. It is relatively common, with physiologic anisocoria accounting for the majority of cases and occurring in approximately 15–30% of the population. In these benign cases, there is no associated ocular or neurologic abnormality. However, anisocoria in children can occasionally indicate underlying pathology, making careful evaluation essential.
The causes of anisocoria range from benign physiologic variation to serious neurologic or ocular disease. Physiologic anisocoria is idiopathic and not associated with any risk factors. Other causes include trauma (ocular or systemic), inflammation such as iritis, meningitis, pharmacologic exposure to mydriatic or miotic agents, and congenital or acquired neurologic conditions. One particularly important cause is Horner syndrome, which may be congenital due to birth trauma or acquired due to neoplasms such as neuroblastoma. Third cranial nerve palsy, whether congenital or acquired, is another critical cause and may result from trauma, infection, tumors, or, rarely in children, aneurysms. Less common causes include Adie’s tonic pupil, pharmacologic dilation, traumatic iris damage, posterior synechiae, and anterior segment dysgenesis.
Pathophysiologically, anisocoria results from dysfunction or imbalance in the pupillary sphincter or dilator muscles, mechanical restriction of the iris, or disruption of the autonomic innervation to the pupil. In some cases, such as physiologic anisocoria, no structural or functional abnormality is identified.
A detailed history is essential in evaluation. Important aspects include the age of onset, duration, history of trauma (including birth trauma), prior surgeries, and associated symptoms such as ptosis, anhidrosis, or facial flushing. Reviewing old photographs can help determine whether the anisocoria is congenital or acquired. Symptoms such as ptosis or abnormal sweating may suggest Horner syndrome, while diplopia or abnormal eye movements may indicate third nerve palsy.
On physical examination, visual acuity is typically normal in physiologic anisocoria but may be reduced in conditions like third nerve palsy or Adie’s pupil due to amblyopia or accommodative dysfunction. Careful pupil examination is crucial. If anisocoria is greater in darkness, the smaller pupil is abnormal, suggesting conditions such as Horner syndrome or physiologic anisocoria. If anisocoria is greater in light, the larger pupil is abnormal, indicating possibilities such as third nerve palsy, Adie’s pupil, traumatic mydriasis, or pharmacologic dilation. Additional findings such as dilation lag, light-near dissociation, segmental iris constriction, iris heterochromia, and eyelid abnormalities can further aid diagnosis. Extraocular motility should also be assessed, as abnormalities may indicate third nerve involvement. A systemic examination, including palpation for masses in the abdomen or neck, is important when a neoplastic cause is suspected.
Diagnostic testing depends on the suspected underlying cause. In suspected Horner syndrome without clear birth trauma, urine testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) may be performed to screen for neuroblastoma, although imaging is often more sensitive. MRI of the brain, neck, chest, and abdomen is typically recommended when Horner syndrome is suspected. If third nerve palsy is suspected, MRI with magnetic resonance angiography may be indicated. Pharmacologic testing can also aid diagnosis: apraclonidine or cocaine drops for Horner syndrome, hydroxyamphetamine to localize the lesion, and dilute pilocarpine for Adie’s tonic pupil.
Management focuses on identifying and treating the underlying cause rather than the anisocoria itself. Physiologic anisocoria requires no treatment. In Adie’s tonic pupil, dilute pilocarpine may be used to improve symptoms and cosmesis. Posterior synechiae due to iritis may be treated with mydriatic agents and anti-inflammatory therapy. Amblyopia, which may occur in conditions like third nerve palsy or Adie’s pupil, should be managed with refractive correction, patching, or atropine penalization. Cosmetic contact lenses may be considered in older children if appearance is a concern. Urgent referral is required if a neoplasm is suspected, and infants with Adie’s pupil should be evaluated by pediatric neurology to exclude systemic disorders.
Follow-up depends on the underlying cause. Physiologic anisocoria does not require ongoing monitoring. Children with third nerve palsy or Adie’s pupil should be followed to monitor for amblyopia. Suspected but unconfirmed Horner syndrome may require reassessment and repeat testing after several months. Conditions such as anterior segment dysgenesis require monitoring for complications like glaucoma.
The prognosis is excellent for physiologic anisocoria, with no impact on vision or development. For other causes, the outcome depends on the underlying condition. Early identification is critical, particularly in cases associated with serious conditions such as neuroblastoma, where prompt diagnosis can be life-saving.
Anisocoria in children refers to a difference in pupil size of 0.5 mm or more between the two eyes. It is relatively common, with physiologic anisocoria accounting for the majority of cases and occurring in approximately 15–30% of the population. In these benign cases, there is no associated ocular or neurologic abnormality. However, anisocoria in children can occasionally indicate underlying pathology, making careful evaluation essential.
The causes of anisocoria range from benign physiologic variation to serious neurologic or ocular disease. Physiologic anisocoria is idiopathic and not associated with any risk factors. Other causes include trauma (ocular or systemic), inflammation such as iritis, meningitis, pharmacologic exposure to mydriatic or miotic agents, and congenital or acquired neurologic conditions. One particularly important cause is Horner syndrome, which may be congenital due to birth trauma or acquired due to neoplasms such as neuroblastoma. Third cranial nerve palsy, whether congenital or acquired, is another critical cause and may result from trauma, infection, tumors, or, rarely in children, aneurysms. Less common causes include Adie’s tonic pupil, pharmacologic dilation, traumatic iris damage, posterior synechiae, and anterior segment dysgenesis.
Pathophysiologically, anisocoria results from dysfunction or imbalance in the pupillary sphincter or dilator muscles, mechanical restriction of the iris, or disruption of the autonomic innervation to the pupil. In some cases, such as physiologic anisocoria, no structural or functional abnormality is identified.
A detailed history is essential in evaluation. Important aspects include the age of onset, duration, history of trauma (including birth trauma), prior surgeries, and associated symptoms such as ptosis, anhidrosis, or facial flushing. Reviewing old photographs can help determine whether the anisocoria is congenital or acquired. Symptoms such as ptosis or abnormal sweating may suggest Horner syndrome, while diplopia or abnormal eye movements may indicate third nerve palsy.
On physical examination, visual acuity is typically normal in physiologic anisocoria but may be reduced in conditions like third nerve palsy or Adie’s pupil due to amblyopia or accommodative dysfunction. Careful pupil examination is crucial. If anisocoria is greater in darkness, the smaller pupil is abnormal, suggesting conditions such as Horner syndrome or physiologic anisocoria. If anisocoria is greater in light, the larger pupil is abnormal, indicating possibilities such as third nerve palsy, Adie’s pupil, traumatic mydriasis, or pharmacologic dilation. Additional findings such as dilation lag, light-near dissociation, segmental iris constriction, iris heterochromia, and eyelid abnormalities can further aid diagnosis. Extraocular motility should also be assessed, as abnormalities may indicate third nerve involvement. A systemic examination, including palpation for masses in the abdomen or neck, is important when a neoplastic cause is suspected.
Diagnostic testing depends on the suspected underlying cause. In suspected Horner syndrome without clear birth trauma, urine testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) may be performed to screen for neuroblastoma, although imaging is often more sensitive. MRI of the brain, neck, chest, and abdomen is typically recommended when Horner syndrome is suspected. If third nerve palsy is suspected, MRI with magnetic resonance angiography may be indicated. Pharmacologic testing can also aid diagnosis: apraclonidine or cocaine drops for Horner syndrome, hydroxyamphetamine to localize the lesion, and dilute pilocarpine for Adie’s tonic pupil.
Management focuses on identifying and treating the underlying cause rather than the anisocoria itself. Physiologic anisocoria requires no treatment. In Adie’s tonic pupil, dilute pilocarpine may be used to improve symptoms and cosmesis. Posterior synechiae due to iritis may be treated with mydriatic agents and anti-inflammatory therapy. Amblyopia, which may occur in conditions like third nerve palsy or Adie’s pupil, should be managed with refractive correction, patching, or atropine penalization. Cosmetic contact lenses may be considered in older children if appearance is a concern. Urgent referral is required if a neoplasm is suspected, and infants with Adie’s pupil should be evaluated by pediatric neurology to exclude systemic disorders.
Follow-up depends on the underlying cause. Physiologic anisocoria does not require ongoing monitoring. Children with third nerve palsy or Adie’s pupil should be followed to monitor for amblyopia. Suspected but unconfirmed Horner syndrome may require reassessment and repeat testing after several months. Conditions such as anterior segment dysgenesis require monitoring for complications like glaucoma.
The prognosis is excellent for physiologic anisocoria, with no impact on vision or development. For other causes, the outcome depends on the underlying condition. Early identification is critical, particularly in cases associated with serious conditions such as neuroblastoma, where prompt diagnosis can be life-saving.
- Published on
Ophthalmology – Anterior Basement Membrane Dystrophy
Anterior basement membrane dystrophy (ABMD) is the most common corneal dystrophy and is also known by several names, including map-dot-fingerprint dystrophy, mare’s tail dystrophy, and Cogan’s microcystic dystrophy. It is characterized by abnormalities in the corneal epithelial basement membrane that lead to irregularities of the corneal surface. Clinically, it is most commonly associated with two distinct presentations: recurrent painful corneal erosions and visual disturbance due to an irregular corneal surface, and management differs depending on which presentation predominates.
ABMD is relatively common, affecting up to 10% of the adult population in the United States, with a higher prevalence in women. It typically presents in the fourth or fifth decade of life and may gradually worsen over time. The condition is usually inherited in an autosomal dominant pattern. It may coexist with other ocular surface disorders, such as Fuchs’ endothelial dystrophy, and can be exacerbated by chronic blepharitis.
The underlying pathophysiology involves abnormalities in the epithelial basement membrane, including thickening, reduplication, and extension into the overlying epithelium. This leads to poor adhesion between the epithelium and underlying layers, as well as entrapment of cellular debris within cyst-like structures. These structural abnormalities result in an irregular corneal surface and predispose the epithelium to recurrent breakdown.
Patients typically present in one of two ways. The first is with recurrent corneal erosions, often characterized by sudden onset of pain upon awakening, accompanied by foreign body sensation, tearing, and photophobia. This occurs because the eyelid adheres to the poorly attached epithelium during sleep and disrupts it when opening. The second presentation involves gradual visual decline due to irregular astigmatism from the abnormal epithelial surface, sometimes accompanied by mild irritation.
On examination, findings vary depending on the presentation. In cases of recurrent erosion, there may be a localized area of loose or absent epithelium along with surrounding characteristic changes of ABMD. In cases presenting with visual disturbance, slit-lamp examination reveals classic map, dot, and fingerprint patterns within the corneal epithelium, often over the visual axis, leading to surface irregularity. Diagnostic evaluation includes visual acuity testing and slit-lamp examination, with corneal topography often demonstrating irregular mires and increased surface irregularity. Anterior segment optical coherence tomography can further delineate epithelial and basement membrane abnormalities. A rigid gas-permeable contact lens trial may help confirm that visual symptoms are due to corneal surface irregularity if vision improves significantly with the lens.
The differential diagnosis depends on the clinical presentation. Painful presentations must be distinguished from other causes of ocular surface irritation such as dry eye disease, infectious or chemical keratitis, trauma, and blepharitis. Visual disturbance must be differentiated from other causes of decreased vision, including cataract, macular disease, optic neuropathy, and other corneal pathologies.
Management is tailored to the presenting symptoms. For recurrent erosions, first-line treatment focuses on aggressive lubrication with artificial tears, gels, or ointments, particularly at bedtime, and advising patients to open their eyes slowly upon waking. Hypertonic saline ointments may be used to reduce epithelial edema. Additional measures include punctal occlusion to improve tear retention and therapeutic bandage contact lenses to protect the corneal surface. Topical nonsteroidal anti-inflammatory drugs and cyclosporine may be used to control inflammation and improve tear production.
For cases that are refractory or recurrent, procedural interventions may be considered. These include mechanical debridement of the epithelium with a diamond-dusted burr, ethanol epitheliectomy, or phototherapeutic keratectomy, all of which aim to improve epithelial adherence and reduce recurrence of erosions.
In patients with visually significant disease, treatment focuses on improving the corneal surface. Superficial keratectomy is commonly performed to remove the abnormal epithelium and irregular basement membrane over the visual axis, allowing regeneration of a smoother epithelial surface. Unlike treatment for erosions, aggressive polishing of Bowman’s layer is generally avoided to reduce the risk of scarring. A bandage contact lens is typically placed postoperatively, and topical antibiotics, steroids, and anti-inflammatory medications are used during healing.
Follow-up is based on symptom recurrence and response to treatment, and interventions may be repeated if necessary. The overall prognosis is excellent for both pain and visual symptoms with appropriate management. However, complications such as secondary infection or subepithelial scarring can occur, particularly following surgical intervention.
Anterior basement membrane dystrophy (ABMD) is the most common corneal dystrophy and is also known by several names, including map-dot-fingerprint dystrophy, mare’s tail dystrophy, and Cogan’s microcystic dystrophy. It is characterized by abnormalities in the corneal epithelial basement membrane that lead to irregularities of the corneal surface. Clinically, it is most commonly associated with two distinct presentations: recurrent painful corneal erosions and visual disturbance due to an irregular corneal surface, and management differs depending on which presentation predominates.
ABMD is relatively common, affecting up to 10% of the adult population in the United States, with a higher prevalence in women. It typically presents in the fourth or fifth decade of life and may gradually worsen over time. The condition is usually inherited in an autosomal dominant pattern. It may coexist with other ocular surface disorders, such as Fuchs’ endothelial dystrophy, and can be exacerbated by chronic blepharitis.
The underlying pathophysiology involves abnormalities in the epithelial basement membrane, including thickening, reduplication, and extension into the overlying epithelium. This leads to poor adhesion between the epithelium and underlying layers, as well as entrapment of cellular debris within cyst-like structures. These structural abnormalities result in an irregular corneal surface and predispose the epithelium to recurrent breakdown.
Patients typically present in one of two ways. The first is with recurrent corneal erosions, often characterized by sudden onset of pain upon awakening, accompanied by foreign body sensation, tearing, and photophobia. This occurs because the eyelid adheres to the poorly attached epithelium during sleep and disrupts it when opening. The second presentation involves gradual visual decline due to irregular astigmatism from the abnormal epithelial surface, sometimes accompanied by mild irritation.
On examination, findings vary depending on the presentation. In cases of recurrent erosion, there may be a localized area of loose or absent epithelium along with surrounding characteristic changes of ABMD. In cases presenting with visual disturbance, slit-lamp examination reveals classic map, dot, and fingerprint patterns within the corneal epithelium, often over the visual axis, leading to surface irregularity. Diagnostic evaluation includes visual acuity testing and slit-lamp examination, with corneal topography often demonstrating irregular mires and increased surface irregularity. Anterior segment optical coherence tomography can further delineate epithelial and basement membrane abnormalities. A rigid gas-permeable contact lens trial may help confirm that visual symptoms are due to corneal surface irregularity if vision improves significantly with the lens.
The differential diagnosis depends on the clinical presentation. Painful presentations must be distinguished from other causes of ocular surface irritation such as dry eye disease, infectious or chemical keratitis, trauma, and blepharitis. Visual disturbance must be differentiated from other causes of decreased vision, including cataract, macular disease, optic neuropathy, and other corneal pathologies.
Management is tailored to the presenting symptoms. For recurrent erosions, first-line treatment focuses on aggressive lubrication with artificial tears, gels, or ointments, particularly at bedtime, and advising patients to open their eyes slowly upon waking. Hypertonic saline ointments may be used to reduce epithelial edema. Additional measures include punctal occlusion to improve tear retention and therapeutic bandage contact lenses to protect the corneal surface. Topical nonsteroidal anti-inflammatory drugs and cyclosporine may be used to control inflammation and improve tear production.
For cases that are refractory or recurrent, procedural interventions may be considered. These include mechanical debridement of the epithelium with a diamond-dusted burr, ethanol epitheliectomy, or phototherapeutic keratectomy, all of which aim to improve epithelial adherence and reduce recurrence of erosions.
In patients with visually significant disease, treatment focuses on improving the corneal surface. Superficial keratectomy is commonly performed to remove the abnormal epithelium and irregular basement membrane over the visual axis, allowing regeneration of a smoother epithelial surface. Unlike treatment for erosions, aggressive polishing of Bowman’s layer is generally avoided to reduce the risk of scarring. A bandage contact lens is typically placed postoperatively, and topical antibiotics, steroids, and anti-inflammatory medications are used during healing.
Follow-up is based on symptom recurrence and response to treatment, and interventions may be repeated if necessary. The overall prognosis is excellent for both pain and visual symptoms with appropriate management. However, complications such as secondary infection or subepithelial scarring can occur, particularly following surgical intervention.
- Published on
Ophthalmology – Arcus Senilis
Arcus senilis is a common ocular finding characterized by a yellowish-white ring of lipid deposition in the peripheral cornea, separated from the limbus by a narrow clear zone. It is most frequently seen in older adults and is considered a benign, age-related change that does not affect vision or require treatment. In younger individuals, however, the presence of arcus—often termed arcus juvenilis—may indicate underlying systemic conditions such as hyperlipidemia and increased cardiovascular risk.
The prevalence of arcus senilis increases with age, affecting a significant proportion of individuals over 50 years old, with estimates around 65%. It is more commonly observed in men and in individuals of African descent. While aging is the primary risk factor in older patients, early onset arcus is strongly associated with disorders of lipid metabolism, particularly familial hypercholesterolemia, an autosomal dominant condition. In such cases, the development of arcus reflects the duration of lipid abnormalities rather than their severity.
Pathophysiologically, arcus senilis results from the deposition of lipids—including cholesterol, cholesterol esters, triglycerides, and phospholipids—within the corneal stroma. These deposits occur primarily in both superficial (Bowman’s membrane) and deep (Descemet’s membrane) layers, forming characteristic wedge-shaped opacities that eventually merge into a circumferential ring. Despite these structural changes, corneal transparency in the visual axis remains unaffected, which is why vision is preserved.
Clinically, patients are usually asymptomatic and may notice only a change in the appearance of their eyes, sometimes describing a lighter ring around the iris. On examination, the arcus appears as a well-defined peripheral ring with a clear zone adjacent to the limbus. It typically begins as superior and inferior arcs that gradually extend to form a complete 360-degree ring. Slit-lamp examination helps to better visualize the depth and distribution of lipid deposits.
Although arcus senilis itself does not impair vision, its clinical significance lies in its association with systemic disease in younger patients. In individuals under 50 years of age, especially men, it is considered a marker for hyperlipidemia and may be associated with increased risk of coronary artery disease and cardiovascular mortality. In children, arcus may be linked to congenital ocular anomalies or inherited lipid disorders, necessitating further evaluation.
Diagnosis is primarily clinical, but in younger patients, laboratory evaluation including serum lipid profile is essential. Additional cardiovascular assessment may be warranted depending on risk factors, including evaluation for hypertension, diabetes, smoking history, and family history of cardiovascular disease. In some cases, further investigations such as electrocardiography or stress testing may be indicated.
The differential diagnosis includes other peripheral corneal rings or opacities such as the Kayser–Fleischer ring seen in Wilson’s disease, band keratopathy from calcium deposition, limbal girdle of Vogt, Terrien’s marginal degeneration, and corneal changes associated with metabolic disorders like lecithin-cholesterol acyltransferase deficiency. These conditions can usually be distinguished based on clinical appearance, location, associated symptoms, and systemic findings.
Management of arcus senilis itself is not required, as it is a benign and non-progressive condition in older adults. However, in patients younger than 50 years, identification of arcus should prompt evaluation for underlying lipid abnormalities and cardiovascular risk factors. Patient education is important, with reassurance provided to older individuals and appropriate counseling and referral offered to younger patients for systemic evaluation.
The prognosis is excellent in terms of ocular health, as arcus senilis does not affect vision. Its significance lies primarily as a potential clinical marker for systemic disease in younger individuals, where early detection and management of associated conditions can have important long-term health benefits.
Arcus senilis is a common ocular finding characterized by a yellowish-white ring of lipid deposition in the peripheral cornea, separated from the limbus by a narrow clear zone. It is most frequently seen in older adults and is considered a benign, age-related change that does not affect vision or require treatment. In younger individuals, however, the presence of arcus—often termed arcus juvenilis—may indicate underlying systemic conditions such as hyperlipidemia and increased cardiovascular risk.
The prevalence of arcus senilis increases with age, affecting a significant proportion of individuals over 50 years old, with estimates around 65%. It is more commonly observed in men and in individuals of African descent. While aging is the primary risk factor in older patients, early onset arcus is strongly associated with disorders of lipid metabolism, particularly familial hypercholesterolemia, an autosomal dominant condition. In such cases, the development of arcus reflects the duration of lipid abnormalities rather than their severity.
Pathophysiologically, arcus senilis results from the deposition of lipids—including cholesterol, cholesterol esters, triglycerides, and phospholipids—within the corneal stroma. These deposits occur primarily in both superficial (Bowman’s membrane) and deep (Descemet’s membrane) layers, forming characteristic wedge-shaped opacities that eventually merge into a circumferential ring. Despite these structural changes, corneal transparency in the visual axis remains unaffected, which is why vision is preserved.
Clinically, patients are usually asymptomatic and may notice only a change in the appearance of their eyes, sometimes describing a lighter ring around the iris. On examination, the arcus appears as a well-defined peripheral ring with a clear zone adjacent to the limbus. It typically begins as superior and inferior arcs that gradually extend to form a complete 360-degree ring. Slit-lamp examination helps to better visualize the depth and distribution of lipid deposits.
Although arcus senilis itself does not impair vision, its clinical significance lies in its association with systemic disease in younger patients. In individuals under 50 years of age, especially men, it is considered a marker for hyperlipidemia and may be associated with increased risk of coronary artery disease and cardiovascular mortality. In children, arcus may be linked to congenital ocular anomalies or inherited lipid disorders, necessitating further evaluation.
Diagnosis is primarily clinical, but in younger patients, laboratory evaluation including serum lipid profile is essential. Additional cardiovascular assessment may be warranted depending on risk factors, including evaluation for hypertension, diabetes, smoking history, and family history of cardiovascular disease. In some cases, further investigations such as electrocardiography or stress testing may be indicated.
The differential diagnosis includes other peripheral corneal rings or opacities such as the Kayser–Fleischer ring seen in Wilson’s disease, band keratopathy from calcium deposition, limbal girdle of Vogt, Terrien’s marginal degeneration, and corneal changes associated with metabolic disorders like lecithin-cholesterol acyltransferase deficiency. These conditions can usually be distinguished based on clinical appearance, location, associated symptoms, and systemic findings.
Management of arcus senilis itself is not required, as it is a benign and non-progressive condition in older adults. However, in patients younger than 50 years, identification of arcus should prompt evaluation for underlying lipid abnormalities and cardiovascular risk factors. Patient education is important, with reassurance provided to older individuals and appropriate counseling and referral offered to younger patients for systemic evaluation.
The prognosis is excellent in terms of ocular health, as arcus senilis does not affect vision. Its significance lies primarily as a potential clinical marker for systemic disease in younger individuals, where early detection and management of associated conditions can have important long-term health benefits.
- Published on
Ophthalmology – Anisometropia
Anisometropia is defined as a difference in refractive error between the two eyes and is one of the most common causes of amblyopia. It becomes particularly amblyogenic when the interocular difference exceeds certain thresholds, such as more than 1.50 diopters of hyperopia, more than 1.00 diopter of astigmatism, or more than 6.00 diopters of myopia. Two main forms are recognized: spherical equivalent anisometropia and astigmatic anisometropia. Because of unequal image clarity between the eyes, the brain preferentially uses the clearer image, leading to suppression of the blurrier eye and impaired visual development.
Anisometropia is relatively common, with a prevalence ranging from 1% to 11% of the population. Among affected individuals, approximately 25–60% develop amblyopia. The condition may change during childhood, but larger degrees of anisometropia, particularly greater than 3 diopters, are more likely to persist. Early detection is critical, as the risk of amblyopia increases with age if untreated, with a significant proportion of young children with anisometropia developing amblyopia over time.
Risk factors include prematurity, especially in association with retinopathy of prematurity, as well as congenital conditions such as ptosis, coloboma, cataract, congenital glaucoma, and microphthalmia. Any condition that leads to asymmetric visual input between the eyes in early life can predispose to anisometropia. Although there is no clear inheritance pattern, a family history increases risk, often reflecting the inheritance of underlying ocular conditions rather than anisometropia itself.
The underlying pathophysiology involves unequal visual input to the brain, which disrupts normal binocular visual development. This imbalance leads to suppression of the image from the more defocused eye and reduced stimulation of the corresponding neurons in the visual cortex. Over time, this results in amblyopia, characterized by decreased visual acuity that cannot be explained by structural abnormalities alone. Functional imaging studies have demonstrated reduced activation in the visual cortex and lateral geniculate nucleus corresponding to the amblyopic eye.
Clinically, anisometropia may present with unequal refractive prescriptions between the eyes or unilateral visual impairment. In some cases, it is detected during routine screening, particularly in children who may not report symptoms. A thorough eye examination is essential, including measurement of visual acuity and a complete dilated examination to exclude other causes of reduced vision. Cycloplegic refraction is critical for accurately identifying the degree of refractive difference between the eyes. Reduced contrast sensitivity may also be observed in anisometropic amblyopia.
The differential diagnosis includes any ocular or neurologic condition that can cause unilateral or asymmetric visual impairment, such as retinal disease, optic nerve pathology, or cortical visual disorders. It is also important to consider structural causes of refractive asymmetry, including differences in axial length, corneal curvature, or lens power.
Management focuses on correcting the refractive error and preventing or treating amblyopia. Spectacle correction is the first-line treatment and may alone lead to significant improvement in visual acuity, with many patients showing improvement over several months. In cases where amblyopia persists, additional therapy is required, typically involving occlusion (patching) of the better-seeing eye or pharmacologic penalization with atropine. Both approaches aim to stimulate use of the amblyopic eye and promote visual development. Contact lenses may be preferred in cases of high anisometropia to reduce image size differences (aniseikonia) and improve cosmetic acceptance.
Follow-up is essential to monitor visual improvement and ensure compliance with treatment. Younger children require more frequent monitoring due to the rapid changes in visual development and the risk of amblyopia. Care must also be taken to avoid occlusion amblyopia in the treated eye. Referral for surgical intervention may be necessary if an underlying structural cause such as cataract or ptosis is identified.
The prognosis is generally good with early detection and appropriate treatment. Many patients experience significant improvement in visual acuity with spectacles alone, and further gains can be achieved with amblyopia therapy. However, delayed treatment reduces the likelihood of full recovery, emphasizing the importance of early screening and intervention. Potential complications include persistent amblyopia and, less commonly, iatrogenic visual loss in the better eye due to overtreatment.
Anisometropia is defined as a difference in refractive error between the two eyes and is one of the most common causes of amblyopia. It becomes particularly amblyogenic when the interocular difference exceeds certain thresholds, such as more than 1.50 diopters of hyperopia, more than 1.00 diopter of astigmatism, or more than 6.00 diopters of myopia. Two main forms are recognized: spherical equivalent anisometropia and astigmatic anisometropia. Because of unequal image clarity between the eyes, the brain preferentially uses the clearer image, leading to suppression of the blurrier eye and impaired visual development.
Anisometropia is relatively common, with a prevalence ranging from 1% to 11% of the population. Among affected individuals, approximately 25–60% develop amblyopia. The condition may change during childhood, but larger degrees of anisometropia, particularly greater than 3 diopters, are more likely to persist. Early detection is critical, as the risk of amblyopia increases with age if untreated, with a significant proportion of young children with anisometropia developing amblyopia over time.
Risk factors include prematurity, especially in association with retinopathy of prematurity, as well as congenital conditions such as ptosis, coloboma, cataract, congenital glaucoma, and microphthalmia. Any condition that leads to asymmetric visual input between the eyes in early life can predispose to anisometropia. Although there is no clear inheritance pattern, a family history increases risk, often reflecting the inheritance of underlying ocular conditions rather than anisometropia itself.
The underlying pathophysiology involves unequal visual input to the brain, which disrupts normal binocular visual development. This imbalance leads to suppression of the image from the more defocused eye and reduced stimulation of the corresponding neurons in the visual cortex. Over time, this results in amblyopia, characterized by decreased visual acuity that cannot be explained by structural abnormalities alone. Functional imaging studies have demonstrated reduced activation in the visual cortex and lateral geniculate nucleus corresponding to the amblyopic eye.
Clinically, anisometropia may present with unequal refractive prescriptions between the eyes or unilateral visual impairment. In some cases, it is detected during routine screening, particularly in children who may not report symptoms. A thorough eye examination is essential, including measurement of visual acuity and a complete dilated examination to exclude other causes of reduced vision. Cycloplegic refraction is critical for accurately identifying the degree of refractive difference between the eyes. Reduced contrast sensitivity may also be observed in anisometropic amblyopia.
The differential diagnosis includes any ocular or neurologic condition that can cause unilateral or asymmetric visual impairment, such as retinal disease, optic nerve pathology, or cortical visual disorders. It is also important to consider structural causes of refractive asymmetry, including differences in axial length, corneal curvature, or lens power.
Management focuses on correcting the refractive error and preventing or treating amblyopia. Spectacle correction is the first-line treatment and may alone lead to significant improvement in visual acuity, with many patients showing improvement over several months. In cases where amblyopia persists, additional therapy is required, typically involving occlusion (patching) of the better-seeing eye or pharmacologic penalization with atropine. Both approaches aim to stimulate use of the amblyopic eye and promote visual development. Contact lenses may be preferred in cases of high anisometropia to reduce image size differences (aniseikonia) and improve cosmetic acceptance.
Follow-up is essential to monitor visual improvement and ensure compliance with treatment. Younger children require more frequent monitoring due to the rapid changes in visual development and the risk of amblyopia. Care must also be taken to avoid occlusion amblyopia in the treated eye. Referral for surgical intervention may be necessary if an underlying structural cause such as cataract or ptosis is identified.
The prognosis is generally good with early detection and appropriate treatment. Many patients experience significant improvement in visual acuity with spectacles alone, and further gains can be achieved with amblyopia therapy. However, delayed treatment reduces the likelihood of full recovery, emphasizing the importance of early screening and intervention. Potential complications include persistent amblyopia and, less commonly, iatrogenic visual loss in the better eye due to overtreatment.
- Published on
Ophthalmology – Acute Anterior Uveitis
Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.
A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.
Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.
Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.
Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.
Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.
Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.
Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.
A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.
Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.
Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.
Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.
Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.
Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.
- Published on
Ophthalmology – Achromatopsia
Achromatopsia is a congenital retinal disorder characterized by reduced or absent color vision due to defective cone photoreceptor function. It presents with photophobia, decreased visual acuity, nystagmus, eccentric fixation, and a small central scotoma. The condition may be classified into complete and incomplete forms, depending on the degree of residual cone function. It typically manifests in infancy, often with fine nystagmus and marked light sensitivity, and children may prefer dim lighting, sometimes being described as “night owls.” Visual acuity is usually reduced, commonly around 20/200, and color discrimination is severely impaired.
The condition has an estimated incidence of approximately 1 in 30,000 individuals and follows an autosomal recessive inheritance pattern. Risk factors include consanguinity and a positive family history. Several genetic mutations have been identified, including CNGA3, CNGB3 (notably the Pingelap variant), GNAT2, and others, all affecting proteins involved in cone phototransduction. The underlying pathophysiology involves reduced or absent expression of these proteins in cone photoreceptors, leading to disruption of the normal phototransduction cascade and abnormal cone development.
Clinically, patients exhibit high-frequency nystagmus that may lessen with age, significant photophobia, and reduced visual acuity. Hyperopia may be present, and fundus examination is often normal or shows only subtle changes such as minimal foveal hypoplasia or mild pigmentary alterations. Color vision testing reveals impairment across all axes (protan, deutan, and tritan). Full-field electroretinography typically demonstrates absent or markedly reduced photopic (cone-mediated) responses with relatively preserved scotopic (rod-mediated) responses. Visual field testing may show a small central scotoma, and optical coherence tomography may appear normal or show mild macular thinning. Additional imaging such as fluorescein angiography and fundus autofluorescence is usually normal.
Diagnosis is supported by clinical findings and can be confirmed with molecular genetic testing. Neuroimaging may be considered in atypical cases, particularly when nystagmus presentation is unusual, to exclude intracranial pathology. Histopathologically, there is a reduced number of cones, and the remaining cones are structurally abnormal.
Differential diagnoses include incomplete achromatopsia, which retains partial cone function and better visual acuity; blue-cone monochromatism, which is X-linked and can be differentiated by specialized color testing or electroretinography; cone monochromatism; cone dystrophy, which shows progressive deterioration rather than congenital onset; and cone-rod dystrophy, which includes rod involvement over time. Other considerations include foveal hypoplasia and cerebral achromatopsia, the latter typically associated with neurological events such as trauma or febrile illness.
There is no specific medical treatment for achromatopsia. Management focuses on supportive measures, including the use of dark or tinted glasses or red-tinted contact lenses to reduce photophobia, although these may not always be well tolerated. Low vision aids are beneficial, and children may require educational support such as individualized learning plans. Correction of refractive error is important, and patients should be referred for genetic counseling and low vision services as needed.
Regular follow-up is recommended, particularly in children, with ophthalmic evaluations every 6 to 12 months to monitor visual function and refractive status. The prognosis is generally stable, with visual acuity remaining relatively constant over time, although mild degeneration may occur later in life due to age-related photoreceptor loss. Nystagmus and photophobia may improve slightly with age. The main complications include persistent low vision and significant light sensitivity, which can impact daily functioning and quality of life.
Achromatopsia is a congenital retinal disorder characterized by reduced or absent color vision due to defective cone photoreceptor function. It presents with photophobia, decreased visual acuity, nystagmus, eccentric fixation, and a small central scotoma. The condition may be classified into complete and incomplete forms, depending on the degree of residual cone function. It typically manifests in infancy, often with fine nystagmus and marked light sensitivity, and children may prefer dim lighting, sometimes being described as “night owls.” Visual acuity is usually reduced, commonly around 20/200, and color discrimination is severely impaired.
The condition has an estimated incidence of approximately 1 in 30,000 individuals and follows an autosomal recessive inheritance pattern. Risk factors include consanguinity and a positive family history. Several genetic mutations have been identified, including CNGA3, CNGB3 (notably the Pingelap variant), GNAT2, and others, all affecting proteins involved in cone phototransduction. The underlying pathophysiology involves reduced or absent expression of these proteins in cone photoreceptors, leading to disruption of the normal phototransduction cascade and abnormal cone development.
Clinically, patients exhibit high-frequency nystagmus that may lessen with age, significant photophobia, and reduced visual acuity. Hyperopia may be present, and fundus examination is often normal or shows only subtle changes such as minimal foveal hypoplasia or mild pigmentary alterations. Color vision testing reveals impairment across all axes (protan, deutan, and tritan). Full-field electroretinography typically demonstrates absent or markedly reduced photopic (cone-mediated) responses with relatively preserved scotopic (rod-mediated) responses. Visual field testing may show a small central scotoma, and optical coherence tomography may appear normal or show mild macular thinning. Additional imaging such as fluorescein angiography and fundus autofluorescence is usually normal.
Diagnosis is supported by clinical findings and can be confirmed with molecular genetic testing. Neuroimaging may be considered in atypical cases, particularly when nystagmus presentation is unusual, to exclude intracranial pathology. Histopathologically, there is a reduced number of cones, and the remaining cones are structurally abnormal.
Differential diagnoses include incomplete achromatopsia, which retains partial cone function and better visual acuity; blue-cone monochromatism, which is X-linked and can be differentiated by specialized color testing or electroretinography; cone monochromatism; cone dystrophy, which shows progressive deterioration rather than congenital onset; and cone-rod dystrophy, which includes rod involvement over time. Other considerations include foveal hypoplasia and cerebral achromatopsia, the latter typically associated with neurological events such as trauma or febrile illness.
There is no specific medical treatment for achromatopsia. Management focuses on supportive measures, including the use of dark or tinted glasses or red-tinted contact lenses to reduce photophobia, although these may not always be well tolerated. Low vision aids are beneficial, and children may require educational support such as individualized learning plans. Correction of refractive error is important, and patients should be referred for genetic counseling and low vision services as needed.
Regular follow-up is recommended, particularly in children, with ophthalmic evaluations every 6 to 12 months to monitor visual function and refractive status. The prognosis is generally stable, with visual acuity remaining relatively constant over time, although mild degeneration may occur later in life due to age-related photoreceptor loss. Nystagmus and photophobia may improve slightly with age. The main complications include persistent low vision and significant light sensitivity, which can impact daily functioning and quality of life.
- Published on
Ophthalmology – Acne Rosacea
Acne rosacea is a chronic inflammatory acneiform disorder that primarily affects the central face, including the nose, cheeks, chin, forehead, and may also involve the eyelids and ocular surface. It commonly presents with facial flushing, persistent erythema, papules, pustules, and a sensation of burning or stinging, often accompanied by dry skin. Ocular involvement is frequent and may manifest as blepharoconjunctivitis with meibomian gland dysfunction, lid margin telangiectasia, recurrent hordeola or chalazia, conjunctival hyperemia, and irritation. In more severe cases, the cornea may be affected, leading to punctate epithelial keratitis, vascularization, infiltration, ulceration, or even perforation. Less commonly, inflammation may extend to the episclera, sclera, or iris.
Rosacea affects approximately 1 in 20 individuals, most commonly between the ages of 30 and 60 years, with no clear sex predilection. It is thought to be more prevalent in fair-skinned individuals of European or Celtic descent, although this may be underrecognized in darker skin due to masking by pigmentation. While no single causative gene has been identified, there is often a familial tendency. The exact etiology remains unclear, with proposed contributing factors including vascular dysregulation, immune and inflammatory mechanisms, environmental triggers, and possibly microorganisms such as Demodex folliculorum. Pathophysiologically, abnormal vascular responses lead to vasodilation and leakage of plasma, which promotes inflammation.
Patients often report a history of facial flushing triggered by environmental or lifestyle factors such as sun exposure, wind, extreme temperatures, exercise, stress, alcohol, or spicy foods. On examination, characteristic findings include diffuse erythema, telangiectasias, inflammatory papules and pustules, and in advanced cases, hypertrophy of sebaceous glands resulting in rhinophyma, which is thickening and purplish discoloration of the nasal skin. Ocular examination may reveal chronic eyelid inflammation, meibomian gland obstruction, and signs of conjunctival or corneal involvement.
Diagnosis is primarily clinical and does not require laboratory testing. Histopathological findings, when assessed, include vascular dilation, perivascular inflammatory infiltrates composed of lymphocytes, plasma cells, and histiocytes, and degeneration of dermal connective tissue with edema and elastosis. In rhinophyma, there is an increase in sebaceous gland tissue. Differential diagnoses include acne vulgaris, lupus erythematosus, seborrheic dermatitis, erysipelas, dermatitis, carcinoid syndrome, tuberculosis, and syphilis.
Management focuses on controlling symptoms and preventing progression, as rosacea is a chronic condition without a definitive cure. First-line treatment typically includes oral tetracyclines such as doxycycline or minocycline, which have both antimicrobial and anti-inflammatory effects. Topical therapies such as metronidazole, azelaic acid, or sodium sulfacetamide may also be used. Lid hygiene is essential in patients with ocular involvement, along with lubricants and, in some cases, short-term topical corticosteroids. More severe or refractory cases may require oral isotretinoin or procedural interventions such as electrocautery for telangiectasias.
Patients should be advised to avoid known triggers, use daily sunscreen, and adopt gentle skincare practices. Dietary modifications, including limiting spicy foods, alcohol, and hot beverages, may help reduce flare-ups. Referral to ophthalmology is important in cases with significant ocular involvement, particularly when there is corneal disease or recurrent eyelid lesions, and dermatology referral may be necessary for severe cutaneous disease or rhinophyma requiring surgical or laser treatment.
Regular follow-up is important to monitor for complications, especially corneal involvement, which can threaten vision if untreated. The overall prognosis is good with appropriate management, although symptoms tend to be chronic and relapsing. Key clinical insights include recognizing that recurrent chalazia or hordeola may indicate underlying ocular rosacea, and that long-term management often relies on a combination of topical and systemic antibiotic therapy along with lifestyle modification.
Acne rosacea is a chronic inflammatory acneiform disorder that primarily affects the central face, including the nose, cheeks, chin, forehead, and may also involve the eyelids and ocular surface. It commonly presents with facial flushing, persistent erythema, papules, pustules, and a sensation of burning or stinging, often accompanied by dry skin. Ocular involvement is frequent and may manifest as blepharoconjunctivitis with meibomian gland dysfunction, lid margin telangiectasia, recurrent hordeola or chalazia, conjunctival hyperemia, and irritation. In more severe cases, the cornea may be affected, leading to punctate epithelial keratitis, vascularization, infiltration, ulceration, or even perforation. Less commonly, inflammation may extend to the episclera, sclera, or iris.
Rosacea affects approximately 1 in 20 individuals, most commonly between the ages of 30 and 60 years, with no clear sex predilection. It is thought to be more prevalent in fair-skinned individuals of European or Celtic descent, although this may be underrecognized in darker skin due to masking by pigmentation. While no single causative gene has been identified, there is often a familial tendency. The exact etiology remains unclear, with proposed contributing factors including vascular dysregulation, immune and inflammatory mechanisms, environmental triggers, and possibly microorganisms such as Demodex folliculorum. Pathophysiologically, abnormal vascular responses lead to vasodilation and leakage of plasma, which promotes inflammation.
Patients often report a history of facial flushing triggered by environmental or lifestyle factors such as sun exposure, wind, extreme temperatures, exercise, stress, alcohol, or spicy foods. On examination, characteristic findings include diffuse erythema, telangiectasias, inflammatory papules and pustules, and in advanced cases, hypertrophy of sebaceous glands resulting in rhinophyma, which is thickening and purplish discoloration of the nasal skin. Ocular examination may reveal chronic eyelid inflammation, meibomian gland obstruction, and signs of conjunctival or corneal involvement.
Diagnosis is primarily clinical and does not require laboratory testing. Histopathological findings, when assessed, include vascular dilation, perivascular inflammatory infiltrates composed of lymphocytes, plasma cells, and histiocytes, and degeneration of dermal connective tissue with edema and elastosis. In rhinophyma, there is an increase in sebaceous gland tissue. Differential diagnoses include acne vulgaris, lupus erythematosus, seborrheic dermatitis, erysipelas, dermatitis, carcinoid syndrome, tuberculosis, and syphilis.
Management focuses on controlling symptoms and preventing progression, as rosacea is a chronic condition without a definitive cure. First-line treatment typically includes oral tetracyclines such as doxycycline or minocycline, which have both antimicrobial and anti-inflammatory effects. Topical therapies such as metronidazole, azelaic acid, or sodium sulfacetamide may also be used. Lid hygiene is essential in patients with ocular involvement, along with lubricants and, in some cases, short-term topical corticosteroids. More severe or refractory cases may require oral isotretinoin or procedural interventions such as electrocautery for telangiectasias.
Patients should be advised to avoid known triggers, use daily sunscreen, and adopt gentle skincare practices. Dietary modifications, including limiting spicy foods, alcohol, and hot beverages, may help reduce flare-ups. Referral to ophthalmology is important in cases with significant ocular involvement, particularly when there is corneal disease or recurrent eyelid lesions, and dermatology referral may be necessary for severe cutaneous disease or rhinophyma requiring surgical or laser treatment.
Regular follow-up is important to monitor for complications, especially corneal involvement, which can threaten vision if untreated. The overall prognosis is good with appropriate management, although symptoms tend to be chronic and relapsing. Key clinical insights include recognizing that recurrent chalazia or hordeola may indicate underlying ocular rosacea, and that long-term management often relies on a combination of topical and systemic antibiotic therapy along with lifestyle modification.
- Published on
Infectious Disease and Microbiology: Hemolytic–Uremic Syndrome (HUS)
Hemolytic–uremic syndrome (HUS) is a serious clinical condition characterized by a triad of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. It is most commonly associated with infection by Shiga toxin–producing bacteria, particularly Escherichia coli O157:H7 (EHEC). HUS primarily affects young children but can occur at any age and is a major cause of acute kidney injury in pediatric populations.
Epidemiologically, HUS is closely linked to infections caused by enterohemorrhagic E. coli, with an incidence of approximately 1–5 cases per 100,000 people annually in industrialized countries. The infection is more common in children under 5 years old and tends to peak during warmer months, particularly from June to September. Although many individuals infected with EHEC develop only mild gastrointestinal symptoms, about 8% of cases during outbreaks progress to HUS, especially in vulnerable populations such as young children and the elderly.
Transmission is primarily food-borne and is strongly associated with the consumption of undercooked ground beef, unpasteurized milk, contaminated water, and fresh produce such as apples or melons. Cattle serve as the main reservoir, often carrying the organism asymptomatically in their intestines. Infection can also spread through person-to-person contact, particularly in settings such as daycare centers and nursing homes. Proper food handling, cooking, and hygiene practices are essential preventive measures.
The pathophysiology of HUS involves the production of Shiga-like toxin by EHEC. This toxin damages endothelial cells, particularly in the kidneys, leading to inflammation, platelet activation, and formation of microthrombi in small blood vessels. These processes result in mechanical destruction of red blood cells (hemolysis), platelet consumption (thrombocytopenia), and reduced renal perfusion, ultimately causing acute kidney injury.
Clinically, infection typically begins with abdominal cramps and watery diarrhea, which progresses within 24 hours to bloody diarrhea in most patients. Nausea and vomiting are common, while fever is usually absent or mild. As HUS develops, signs such as decreased urine output (oliguria), pallor from anemia, and fatigue become evident. The drop in hematocrit and platelet count are early laboratory indicators of disease progression.
Diagnosis is based on clinical findings and laboratory confirmation. Stool cultures using special media are required to identify EHEC, as routine cultures may miss the organism. Laboratory findings in HUS include anemia with fragmented red blood cells (schistocytes), elevated lactate dehydrogenase (LDH), low haptoglobin, thrombocytopenia, and elevated creatinine levels indicating renal impairment. Urinalysis may show hematuria and proteinuria.
Management of HUS is primarily supportive. Antibiotics are generally not recommended in EHEC infections, as they may increase toxin release and worsen the condition. Similarly, antimotility agents should be avoided because they can enhance toxin absorption. Treatment focuses on maintaining fluid and electrolyte balance, managing renal failure with dialysis if necessary, and providing blood transfusions when indicated. In severe cases, plasmapheresis may be used.
The prognosis of HUS varies depending on severity and patient factors. Despite advances in supportive care, mortality rates range from 5% to 20%, with higher rates in older adults. Among survivors, long-term complications are common, including chronic kidney disease and hypertension, with many patients eventually requiring dialysis or kidney transplantation.
Complications of HUS include severe anemia, thrombocytopenia, electrolyte disturbances, rhabdomyolysis, and permanent renal damage. Additionally, EHEC infection itself may cause hemorrhagic colitis or, less commonly, conditions such as thrombotic thrombocytopenic purpura. Early recognition and supportive management are critical to improving outcomes.
- Published on
Ophthalmology – Acute Retinal Necrosis (Necrotizing Herpetic Retinitis)
Acute retinal necrosis is a severe, vision-threatening infectious retinitis caused by members of the herpes virus family, most commonly varicella zoster virus and herpes simplex virus. It is characterized by a combination of anterior uveitis, vitritis, and rapidly progressive peripheral retinal necrosis that spreads circumferentially and posteriorly, often accompanied by occlusive retinal vasculitis and a high risk of retinal detachment. Despite being a rare condition, with an estimated incidence of approximately 1 case per 1.6–2.0 million individuals, it typically affects otherwise healthy, immunocompetent individuals and shows a bimodal age distribution, most commonly occurring around ages 20 and 50.
Risk factors include a history of herpetic infections such as herpes simplex keratitis, herpes zoster ophthalmicus, cold sores, chickenpox, encephalitis, or shingles. Although immunodeficiency may contribute, most cases occur in immunocompetent patients. Genetic predispositions have been described, with certain HLA types associated with different populations and disease severity. The pathophysiology involves reactivation or primary infection of herpes viruses, which travel via axonal pathways to the retina, leading to viral replication within retinal cells. This results in full-thickness retinal necrosis, intranuclear viral inclusions, and both granulomatous and non-granulomatous inflammation affecting ocular tissues.
Patients may initially present with relatively mild symptoms such as eye redness, irritation, photophobia, floaters, and periorbital pain, although many experience sudden vision loss. On examination, there is often evidence of anterior uveitis, including keratic precipitates and inflammatory activity in the anterior chamber, as well as vitritis. Within days, characteristic posterior segment findings develop, including multifocal, well-demarcated patches of yellow-white retinal necrosis in the peripheral retina. These lesions rapidly progress circumferentially and posteriorly, often sparing the macula initially. Retinal vasculitis with vascular sheathing and hemorrhages may also be present. Over time, complications such as proliferative vitreoretinopathy lead to retinal breaks and rhegmatogenous retinal detachment, which occurs in more than half of cases, typically within one to two months. Bilateral involvement is seen in about 20% of patients at presentation, and without treatment, the second eye may become affected within months.
Diagnosis is primarily clinical, guided by established criteria that include peripheral retinal necrosis, rapid progression, occlusive vasculopathy, and significant intraocular inflammation. Laboratory confirmation can be achieved using polymerase chain reaction testing of aqueous or vitreous samples, which provides high sensitivity and specificity for identifying viral DNA. Other diagnostic methods, such as antibody testing or cultures, may support the diagnosis but are less definitive. Serial fundus photography is useful for monitoring disease progression, and careful examination of both eyes is essential due to the risk of bilateral spread.
The differential diagnosis includes other infectious and inflammatory retinal conditions such as progressive outer retinal necrosis, cytomegalovirus retinitis, toxoplasmosis, syphilitic retinitis, Behçet disease, sarcoidosis, intraocular lymphoma, and fungal endophthalmitis. Management requires urgent antiviral therapy to limit retinal destruction and reduce complications. Treatment traditionally involved intravenous acyclovir followed by prolonged oral therapy, but newer regimens include oral antivirals such as valacyclovir or famciclovir, often combined with intravitreal antiviral injections such as foscarnet or ganciclovir. Adjunctive corticosteroids are frequently used to control inflammation, and topical steroids are commonly administered for anterior segment involvement.
Patients should be urgently referred to a retinal or uveitis specialist due to the aggressive nature of the disease and the potential need for surgical intervention. Prophylactic laser retinopexy may be considered to reduce the risk of retinal detachment, although its benefit remains debated. Vitrectomy is indicated in cases of dense vitreous opacities, hemorrhage, or established retinal detachment. Close monitoring is essential, particularly during the early course, to detect progression, bilateral involvement, or complications.
The prognosis remains guarded despite advances in antiviral therapy, with many patients experiencing significant vision loss. Retinal detachment is the most common and serious complication, and visual outcomes are often poor, with a substantial proportion of patients developing vision worse than 20/200 over time. Other complications include optic nerve involvement, vitreous hemorrhage, retinal neovascularization, and eventual blindness. Early recognition and aggressive treatment are critical to improving outcomes and preserving vision.
Acute retinal necrosis is a severe, vision-threatening infectious retinitis caused by members of the herpes virus family, most commonly varicella zoster virus and herpes simplex virus. It is characterized by a combination of anterior uveitis, vitritis, and rapidly progressive peripheral retinal necrosis that spreads circumferentially and posteriorly, often accompanied by occlusive retinal vasculitis and a high risk of retinal detachment. Despite being a rare condition, with an estimated incidence of approximately 1 case per 1.6–2.0 million individuals, it typically affects otherwise healthy, immunocompetent individuals and shows a bimodal age distribution, most commonly occurring around ages 20 and 50.
Risk factors include a history of herpetic infections such as herpes simplex keratitis, herpes zoster ophthalmicus, cold sores, chickenpox, encephalitis, or shingles. Although immunodeficiency may contribute, most cases occur in immunocompetent patients. Genetic predispositions have been described, with certain HLA types associated with different populations and disease severity. The pathophysiology involves reactivation or primary infection of herpes viruses, which travel via axonal pathways to the retina, leading to viral replication within retinal cells. This results in full-thickness retinal necrosis, intranuclear viral inclusions, and both granulomatous and non-granulomatous inflammation affecting ocular tissues.
Patients may initially present with relatively mild symptoms such as eye redness, irritation, photophobia, floaters, and periorbital pain, although many experience sudden vision loss. On examination, there is often evidence of anterior uveitis, including keratic precipitates and inflammatory activity in the anterior chamber, as well as vitritis. Within days, characteristic posterior segment findings develop, including multifocal, well-demarcated patches of yellow-white retinal necrosis in the peripheral retina. These lesions rapidly progress circumferentially and posteriorly, often sparing the macula initially. Retinal vasculitis with vascular sheathing and hemorrhages may also be present. Over time, complications such as proliferative vitreoretinopathy lead to retinal breaks and rhegmatogenous retinal detachment, which occurs in more than half of cases, typically within one to two months. Bilateral involvement is seen in about 20% of patients at presentation, and without treatment, the second eye may become affected within months.
Diagnosis is primarily clinical, guided by established criteria that include peripheral retinal necrosis, rapid progression, occlusive vasculopathy, and significant intraocular inflammation. Laboratory confirmation can be achieved using polymerase chain reaction testing of aqueous or vitreous samples, which provides high sensitivity and specificity for identifying viral DNA. Other diagnostic methods, such as antibody testing or cultures, may support the diagnosis but are less definitive. Serial fundus photography is useful for monitoring disease progression, and careful examination of both eyes is essential due to the risk of bilateral spread.
The differential diagnosis includes other infectious and inflammatory retinal conditions such as progressive outer retinal necrosis, cytomegalovirus retinitis, toxoplasmosis, syphilitic retinitis, Behçet disease, sarcoidosis, intraocular lymphoma, and fungal endophthalmitis. Management requires urgent antiviral therapy to limit retinal destruction and reduce complications. Treatment traditionally involved intravenous acyclovir followed by prolonged oral therapy, but newer regimens include oral antivirals such as valacyclovir or famciclovir, often combined with intravitreal antiviral injections such as foscarnet or ganciclovir. Adjunctive corticosteroids are frequently used to control inflammation, and topical steroids are commonly administered for anterior segment involvement.
Patients should be urgently referred to a retinal or uveitis specialist due to the aggressive nature of the disease and the potential need for surgical intervention. Prophylactic laser retinopexy may be considered to reduce the risk of retinal detachment, although its benefit remains debated. Vitrectomy is indicated in cases of dense vitreous opacities, hemorrhage, or established retinal detachment. Close monitoring is essential, particularly during the early course, to detect progression, bilateral involvement, or complications.
The prognosis remains guarded despite advances in antiviral therapy, with many patients experiencing significant vision loss. Retinal detachment is the most common and serious complication, and visual outcomes are often poor, with a substantial proportion of patients developing vision worse than 20/200 over time. Other complications include optic nerve involvement, vitreous hemorrhage, retinal neovascularization, and eventual blindness. Early recognition and aggressive treatment are critical to improving outcomes and preserving vision.
